Some Medicare beneficiaries are getting access to weight loss drugs this month through a so-called Bridge program. But ...
Millions could meet criteria to receive GLP-1s, which could cost Medicare billions of dollars, according to a report by KFF.
Medicare is rolling out a new program that will provide low-cost access to GLP-1s for weight loss.
Eli Lilly (LLY) stock and Novo Nordisk (NVO) stock are in focus as Medicare offers coverage for GLP-1 weight-loss drugs for ...
A new CMS pilot gives seniors $50 access to GLP-1 drugs like Wegovy, potentially reshaping food demand, nutrition strategies ...
For the first time ever, Medicare will cover drugs like Wegovy and Zepbound. But a strict BMI checklist and a 2027 deadline ...
The Medicare GLP-1 Bridge Program has opened and will remain open through 2027, giving some Medicare beneficiaries greater ...
The Centers for Medicare & Medicaid Services launched the Medicare GLP-1 Bridge program, an initiative designed to test the impact of increased access to GLP-1 drugs for weight management among ...
The program's demonstration run will last from July 1, 2026, until December 31, 2027, Medicare said.
The Centers for Medicare & Medicaid Services July 1 launched the Medicare GLP-1 Bridge, a short-term demonstration program designed to provide eligible Medicare Part D beneficiaries with access to ...
A Medicare pilot program could expand access to GLP-1 weight-loss drugs for millions of seniors while lowering monthly costs to about $50.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results